BioLineRx Ltd.
BLRX
$2.75
-$0.32-10.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.18M | 12.74M | 17.25M | 22.34M | 28.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.18M | 12.74M | 17.25M | 22.34M | 28.94M |
| Cost of Revenue | 230.00K | 6.28M | 7.02M | 7.84M | 9.26M |
| Gross Profit | 950.00K | 6.46M | 10.23M | 14.50M | 19.68M |
| SG&A Expenses | 3.14M | 8.99M | 15.11M | 22.94M | 29.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.47M | 22.81M | 30.50M | 39.06M | 48.09M |
| Operating Income | -10.29M | -10.07M | -13.25M | -16.72M | -19.15M |
| Income Before Tax | -2.03M | -2.98M | -7.82M | -3.40M | -9.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.03 | -2.98 | -7.82 | -3.40 | -9.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 851.00K | -- | -- | -- | -- |
| Net Income | -1.18M | -2.98M | -7.82M | -3.40M | -9.22M |
| EBIT | -10.29M | -10.07M | -13.25M | -16.72M | -19.15M |
| EBITDA | -9.77M | -7.83M | -10.29M | -13.46M | -15.16M |
| EPS Basic | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 9.86B | 8.50B | 7.09B | 5.92B | 4.79B |
| Average Diluted Shares Outstanding | 9.86B | 8.50B | 7.09B | 5.92B | 4.79B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |